Karolinska Development AB ser. B (KDEV) - Total Assets
Based on the latest financial reports, Karolinska Development AB ser. B (KDEV) holds total assets worth Skr1.05 Billion SEK (≈ $113.34 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Karolinska Development AB ser. B for net asset value and shareholders' equity analysis.
Karolinska Development AB ser. B - Total Assets Trend (2007–2025)
This chart illustrates how Karolinska Development AB ser. B's total assets have evolved over time, based on quarterly financial data.
Karolinska Development AB ser. B - Asset Composition Analysis
Current Asset Composition (December 2025)
Karolinska Development AB ser. B's total assets of Skr1.05 Billion consist of 2.6% current assets and 97.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 2.3% |
| Accounts Receivable | Skr3.35 Million | 0.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Karolinska Development AB ser. B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KDEV company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Karolinska Development AB ser. B's current assets represent 2.6% of total assets in 2025, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 2.3% of total assets in 2025, down from 11.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Karolinska Development AB ser. B Competitors by Total Assets
Key competitors of Karolinska Development AB ser. B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Karolinska Development AB ser. B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.45 | 4.36 | 9.40 |
| Quick Ratio | 24.45 | 4.36 | 13.19 |
| Cash Ratio | 0.00 | 3.17 | 0.00 |
| Working Capital | Skr26.15 Million | Skr44.52 Million | Skr93.34 Million |
Karolinska Development AB ser. B - Advanced Valuation Insights
This section examines the relationship between Karolinska Development AB ser. B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.18 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -15.9% |
| Total Assets | Skr1.05 Billion |
| Market Capitalization | $29.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Karolinska Development AB ser. B's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Karolinska Development AB ser. B's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Karolinska Development AB ser. B (2007–2025)
The table below shows the annual total assets of Karolinska Development AB ser. B from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.05 Billion ≈ $113.34 Million |
-15.88% |
| 2024-12-31 | Skr1.25 Billion ≈ $134.73 Million |
-0.51% |
| 2023-12-31 | Skr1.26 Billion ≈ $135.42 Million |
+0.54% |
| 2022-12-31 | Skr1.25 Billion ≈ $134.70 Million |
+12.83% |
| 2021-12-31 | Skr1.11 Billion ≈ $119.38 Million |
+24.63% |
| 2020-12-31 | Skr890.08 Million ≈ $95.79 Million |
-23.71% |
| 2019-12-31 | Skr1.17 Billion ≈ $125.56 Million |
+46.87% |
| 2018-12-31 | Skr794.38 Million ≈ $85.49 Million |
+19.77% |
| 2017-12-31 | Skr663.26 Million ≈ $71.38 Million |
+51.32% |
| 2016-12-31 | Skr438.32 Million ≈ $47.17 Million |
-28.67% |
| 2015-12-31 | Skr614.46 Million ≈ $66.13 Million |
-64.07% |
| 2014-12-31 | Skr1.71 Billion ≈ $184.06 Million |
-9.78% |
| 2013-12-31 | Skr1.90 Billion ≈ $204.01 Million |
-14.41% |
| 2012-12-31 | Skr2.21 Billion ≈ $238.37 Million |
-5.58% |
| 2011-12-31 | Skr2.35 Billion ≈ $252.45 Million |
+32.26% |
| 2010-12-31 | Skr1.77 Billion ≈ $190.87 Million |
-13.00% |
| 2009-12-31 | Skr2.04 Billion ≈ $219.38 Million |
+22.51% |
| 2008-12-31 | Skr1.66 Billion ≈ $179.08 Million |
+14.62% |
| 2007-12-31 | Skr1.45 Billion ≈ $156.23 Million |
-- |
About Karolinska Development AB ser. B
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in th… Read more